Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients with Borderline Elevation of International Normalized Ratio

Overview

Journal J Vasc Interv Neurol

Date 2013 Dec 21

PMID 24358409

Citations 3

Authors

Harsh R Aggarwal

Ameer E Hassan

Gustavo J Rodriguez

M Fareed K Suri

Robert A Taylor

Adnan I Qureshi

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the rates of symptomatic intracerebral hemorrhages (sICH), parenchymal hematoma type 2 (PH2), and favorable outcomes in patients with borderline elevation of international normalized ratio (INR) or recent anticoagulation use prior to treatment with intravenous recombinant tissue plasminogen activator (IV rt-PA) for acute ischemic stroke.

Methods: Consecutive patients with acute ischemic stroke that received IV rt-PA were identified. History of recent use of anticoagulation and the INR at presentation and after use of thrombolytics, up to 72 h was recorded. Neuroimaging and clinical charts were reviewed for evidence of sICH. Outcomes were recorded at the time of discharge and on follow-up up to 6 months using the modified Rankin scale (mRS).

Results: A total of 106 patients (mean age was 65.95 ± 15.29 years and 55.67% were men) were identified. Of these, 12 (11.3%) patients had initial INR elevation (1.2-1.7) and 12 (11.3%) patients that had recently received oral anticoagulation. The rate of PH2 was higher in patients on anticoagulation or with elevated initial INR compared to patients with normal INR and no history of anticoagulation (15.79% versus 2.30%, P = 0.023). In subgroup analyses, elevation of INR during the first 24 h and history of recent use of anticoagulation in a different analysis inversely correlated with favorable outcomes at discharge and at follow-up.

Conclusion: Borderline elevation in INR or recent use of anticoagulation before thrombolytic use can increase the rate of ICH in patients treated with IV rt-PA for acute ischemic stroke. These patients should cautiously receive thrombolytics for acute ischemic stroke as per the AHA/ASA Stroke Council guidelines.

Citing Articles

Acute Ischemic Stroke and Heart Failure: Stroke Risk Factors Associated with Exclusion from Thrombolytic Therapy.

Sanders C, Knisely K, Rathfoot C, Edrissi C, Nathaniel T Clin Appl Thromb Hemost. 2022; 28:10760296221116347.

PMID: 36278505 PMC: 9596934. DOI: 10.1177/10760296221116347.

Predictors of Radiographic and Symptomatic Hemorrhagic Conversion Following Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion.

Javed K, Boyke A, Naidu I, Ryvlin J, Fluss R, Fortunel A Cureus. 2022; 14(4):e24449.

PMID: 35637796 PMC: 9129917. DOI: 10.7759/cureus.24449.

Differentiating intraparenchymal hemorrhage from contrast extravasation on post-procedural noncontrast CT scan in acute ischemic stroke patients undergoing endovascular treatment.

Payabvash S, Qureshi M, Khan S, Khan M, Majidi S, Pawar S Neuroradiology. 2014; 56(9):737-44.

PMID: 24925217 DOI: 10.1007/s00234-014-1381-8.

References

Saqqur M, Tsivgoulis G, Molina C, Demchuk A, Siddiqui M, Alvarez-Sabin J . Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA: a multicenter study. Neurology. 2008; 71(17):1304-12. DOI: 10.1212/01.wnl.0000313936.15842.0d. View

Hylek E, Singer D . Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994; 120(11):897-902. DOI: 10.7326/0003-4819-120-11-199406010-00001. View

Bonita R, Beaglehole R . Recovery of motor function after stroke. Stroke. 1988; 19(12):1497-500. DOI: 10.1161/01.str.19.12.1497. View

Gage B, Fihn S, White R . Management and dosing of warfarin therapy. Am J Med. 2000; 109(6):481-8. DOI: 10.1016/s0002-9343(00)00545-3. View

. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2005; 112(24 Suppl):IV1-203. DOI: 10.1161/CIRCULATIONAHA.105.166550. View

Williams L, Yilmaz E . Retrospective assessment of initial stroke severity with the NIH Stroke Scale. Stroke. 2001; 31(4):858-62. DOI: 10.1161/01.str.31.4.858. View

Lansberg M, Albers G, Wijman C . Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007; 24(1):1-10. DOI: 10.1159/000103110. View

Adams Jr H, Del Zoppo G, Alberts M, Bhatt D, Brass L, Furlan A . Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the.... Stroke. 2007; 38(5):1655-711. DOI: 10.1161/STROKEAHA.107.181486. View

Berger C, Fiorelli M, Steiner T, Schabitz W, Bozzao L, Bluhmki E . Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic?. Stroke. 2001; 32(6):1330-5. DOI: 10.1161/01.str.32.6.1330. View

10.

Stanley A, Fletcher S, Tan A, Barnett D . Is warfarin a contraindication to thrombolysis in acute ST elevation myocardial infarction?. Heart. 2006; 92(8):1145-146. PMC: 1861091. DOI: 10.1136/hrt.2005.062158. View

11.

Larrue V, von Kummer R R, Muller A, Bluhmki E . Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001; 32(2):438-41. DOI: 10.1161/01.str.32.2.438. View

12.

Hylek E, Go A, Chang Y, Jensvold N, Henault L, Selby J . Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349(11):1019-26. DOI: 10.1056/NEJMoa022913. View

13.

White R, McKittrick T, Hutchinson R, Twitchell J . Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995; 122(1):40-2. DOI: 10.7326/0003-4819-122-1-199501010-00006. View

14.

Mohammad Y, Xavier A, Christoforidis G, Bourekas E, Slivka A . Qureshi grading scheme for angiographic occlusions strongly correlates with the initial severity and in-hospital outcome of acute ischemic stroke. J Neuroimaging. 2004; 14(3):235-41. DOI: 10.1177/1051228404265716. View

15.

Hirsh J, Poller L . The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med. 1994; 154(3):282-8. DOI: 10.1001/archinte.154.3.282. View

16.

Wityk R, Pessin M, Kaplan R, Caplan L . Serial assessment of acute stroke using the NIH Stroke Scale. Stroke. 1994; 25(2):362-5. DOI: 10.1161/01.str.25.2.362. View

17.

Brass L, Lichtman J, Wang Y, Gurwitz J, Radford M, Krumholz H . Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke. 2000; 31(8):1802-11. DOI: 10.1161/01.str.31.8.1802. View

18.

Kandzari D, Granger C, Simoons M, White H, Simes J, Mahaffey K . Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). Am J Cardiol. 2004; 93(4):458-61. DOI: 10.1016/j.amjcard.2003.10.043. View

19.

. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24):1581-7. DOI: 10.1056/NEJM199512143332401. View

20.

Mericle R, Lopes D, Fronckowiak M, Wakhloo A, Guterman L, Hopkins L . A grading scale to predict outcomes after intra-arterial thrombolysis for stroke complicated by contrast extravasation. Neurosurgery. 2000; 46(6):1307-14; discussion 1314-5. DOI: 10.1097/00006123-200006000-00005. View